International Journal of Drug Delivery Technology
Volume 14, Issue 3

Optimizing Orphan Drug Rucaparib Transdermal Patches for Ovarian Cancer: A Design Expert-Based Strategy for Prolonged Drug Release

Hina Deepak Mehta1, Saravanakumar Kasimedu2*, Bharath Raj KC3, Vema Kiran4

1Nagpur College of Pharmacy Wanadongri Hingna Road Nagpur, Maharashtra.

2Department of Pharmaceutics, Seven Hills College of Pharmacy, Venkatramapuram, Tirupati, Andhra Pradesh, India. 3NITTE (Deemed to be University), NGSM Institute of Pharmaceutical Sciences, Department of Pharmacology, Paneer, Deralakatte, Mangalore, Karnataka, India.

4Department of Pharmaceutics, MB School of Pharmaceutical Sciences, Mohan Babu University, Rangampet, Tirupati, Andhra Pradesh, India.

 Received: 07th March, 2024; Revised: 04th May, 2024; Accepted: 15thJuly, 2024; Available Online: 25th September, 2024

 ABSTRACT

This study aimed to develop and characterize transdermal patches for rucaparib using a Box-Behnken design (BBD), evaluating drug permeation at 8, 12, and 24 hours, with optimization through Design Expert software. The patches were formulated with HPMC K15, ethyl cellulose, and PVP K30. The physicochemical properties and drug infusion were tested and characterized. The transdermal patches developed in this study were found to be soft and flexible, indicating good handling properties and potential for comfortable application. The patches demonstrated sustained drug release, extending beyond 24 hours, which is crucial for preserving consistent beneficial levels of rucaparib in the systemic circulation. The optimal formulation, as identified through the BBD using Design Expert software, included HPMC K15 (100 mg), ethyl cellulose (200 mg), and PVP K30 (40 mg). This combination effectively facilitated prolonged drug penetration while keeping the flexibility and integrity of the patches. The study concludes that the formulated transdermal patches using HPMC K15, ethyl cellulose, and PVP K30 offer an effective means for prolonged delivery of DPZ and MMZ. The optimized patches support sustained discharge for a prolonged time, which can improve patient compliance and therapeutic outcomes in treating ovarian cancer. The use of a systematic design approach, such as the BBD, proved beneficial in optimizing the formulation parameters, ensuring the development of high-quality transdermal patches with desirable properties for clinical application.

Keywords: Box Behnken Design, Drug permeation, Orphan drug, Ovarian cancer, patch. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.27

How to cite this article: Mehta HD, Kasimedu S, Raj BKC, Kiran V. Optimizing Orphan Drug Rucaparib Transdermal Patches for Ovarian Cancer: A Design Expert-Based Strategy for Prolonged Drug Release. International Journal of Drug Delivery Technology. 2024;14(3):1441-1449.

REFERENCES

  1. Costa E, Moja L, Wirtz VJ, van den Ham HA, Huttner B, Magrini N, Leufkens HG. Uptake of orphan drugs in the WHO essential medicines lists. Bulletin of the World Health Organization. 2024;102(1):22. https://doi.org/10.2471%2FBLT.23.289731.
  2. Chen Q, Xu Y, Qu R, Luo X, Yang Y. Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023. Drug Discovery Today. 2024:104102. https://doi. org/10.1016/j.drudis.2024.104102.
  3. Attwood MM, Rask-Andersen M, Schiöth HB. Orphan drugs and their impact on pharmaceutical development. Trends in pharmacological sciences. 2018;39(6):525-535. https://doi. org/10.1016/j.tips.2018.03.003
  4. Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP inhibition in cancer: an update on clinical Targeted oncology. 2019;14:657-679. https://doi.org/10.1007/s11523-019-00680-2.
  5. Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents-A recent European journal of medicinal chemistry. 2019;165:198-215. https://doi.org/10.1016/j.ejmech.2019.01.024
  6. Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, Seiller A, Liste-Hermoso M, Willis J, Shemesh CS, Xiao PARPinhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. British Journal of Cancer. 2024:1-12. https://doi.org/10.1038/s41416-024-02776-7.
  7. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical 2020;38(32):3763-3772. https://doi. org/10.1200/JCO.20.01035.
  8. Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J, Frew J, Gale J, Faust G. A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology. 2023;41(1):54-64. https://doi.org/10.1200/JCO.22.00405.
  9. Kristeleit R, O’Malley D, Lim MC, McNeish I, Herzog TJ, Wilson M, Fehm TN, Coleman RL, Van Gorp T, Oza AM, Mikheeva 49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO. ESMO open. 2024;9:10. https://doi.org/10.1016/j.esmoop.2024.103556
  10. Pérez-Peiró M, Valentí-Serra P, León-González B, Ampurdanés C, Duran X, Yélamos J, Barreiro Attenuation of tumor burden in response to rucaparib in lung adenocarcinoma: the contribution of oxidative stress, apoptosis, and DNA damage. International Journal of Molecular Sciences. 2023;24(3):2580. https://doi. org/10.3390/ijms24032580.
  11. Mundarinti SH, Ahad HA. Past decade attempts on gastro retentive microspheres using factorial design: A comprehensive International Journal of Pharmaceutical and Phytopharmacological Research. 2021;11:24-30.
  12. Basha DC, Sudha BN. Box Indian Journal of Pharmaceutical Education and Research. 2024;58(2s):s412-419. https://doi.org/10.5530/ijper.58.2s.44
  13. Ahad HA, Chinthaginjala H, Rahamtulla S, Pallavi BP, Shashanka C, Prathyusha J. A comprehensive report on solid dispersions by factorial design.2021;14(4):297-301. http://dx.doi. org/10.52711/0974-4150.2021.00051
  14. Babu GN, Muthukarupan M, Ahad HA, Sreedhar Fabrication and Preliminary Assessment of Neem Fruit Mucilage as Mucoadhesive Abetting Assets with Methpol-934P for Acyclovir Delivery from Mucoadhesive Microcapsules. Biomedical and Pharmacology Journal. 2022;15(4):2179-2184. https://dx.doi. org/10.13005/bpj/2554.
  15. Ahad HA, Chinthaginjala H, Priyanka MS, Raghav DR, Gowthami M, Jyothi VN. Datura stramonium Leaves Mucilage Aided Buccoadhesive Films of Aceclofenac using 3² Factorial Design with Design-Expert Software. Indian Journal of Pharmaceutical Education & Research. 2021;55(2). DOI: 10.5530/ 55.2s.111.
  16. Bácskay I, Hosszú Z, Budai I, Ujhelyi Z, Fehér P, Kósa D, Haimhoffer Á, Pető Á. Formulation and Evaluation of Transdermal Patches Containing BGP-15. Pharmaceutics. 2023;16(1):36. https://doi.org/10.3390/pharmaceutics16010036.
  17. Almazan EA, Castañeda PS, Torres RD, Escobar-Chavez JJ. Design and evaluation of losartan transdermal patch by using solid microneedles as a physical permeation enhancer. Iranian Journal of Pharmaceutical Research: 2020;19(1):138-152.https://doi.org/10.22037%2Fijpr.2019.1100912.
  18. Su Y, Lu W, Fu X, Xu Y, Ye L, Yang J, Huang H, Yu C. Formulation and pharmacokinetic evaluation of a drug-in- adhesive patch for transdermal delivery of koumine. AAPS PharmSciTech. 2020;21:1-11. https://doi.org/10.1208/s12249- 020-01793-y.
  19. Ashfaq A, Riaz T, Waqar MA, Zaman M, Majeed I. A comprehensive review on transdermal patches as an efficient approach for the delivery of Polymer-Plastics Technology and Materials. 2024;63(8):1045-1069. https://doi.org/10.1080/25 740881.2024.2317408.
  20. Lei Y, Yang G, Du F, Yi J, Quan L, Liu H, Zhou X, Gong W, Han J, Wang Y, Gao C. Formulation and evaluation of a drug-in-adhesive patch for transdermal delivery of Pharmaceutics. 2022;14(10):2245. https://doi.org/10.3390/pharmaceutics14102245.
  21. Pu T, Li X, Sun Y, Ding X, Pan Y, Wang Q. Development of a prolonged-release pramipexole transdermal patch: In vitro and in vivo evaluation. AAPS PharmSciTech. 2017;18:738-748. https:// doi.org/10.1208/s12249-016-0555-6.
  22. Robillard L, Nguyen M, Harding TC, Simmons In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib. Cancer Research. 2017 Jul 1;77(13_Supplement):2475. https://doi.org/10.1158/1538-7445.AM2017-2475.
  23. Islam R, Nabila FH, Wakabayashi R, Kamiya N, Moniruzzaman M, Goto Ionic Liquid-Based patch formulation for enhanced transdermal delivery of sparingly soluble drug. Journal of Molecular Liquids. 2024;397:124184. https://doi.org/10.1016/j. molliq.2024.124184.
  24. Wong WF, Ang KP, Sethi G, Looi Recent advancement of medical patch for transdermal drug delivery. Medicina. 2023;59(4):778. https://doi.org/10.3390/medicina59040778.
  25. Maan S, Khar RK, Mazumder R, Yadav N, Khan Fabrication and Evaluation of Controlled Release Transdermal Drug Delivery System of Carvedilol using Design Expert® Software for the Management of Hypertension. Journal of Young Pharmacists. 2022;14(3):295-301. DOI: 10.5530/jyp.2022.14.58.
  26. Devhare LD and Gokhale Antioxidant and Antiulcer Property of Different Solvent Extracts of Cassia Tora Linn. Research Journal of Pharmacy and Technology. 2022;15(3);1109-1113.
  27. Tiwari R, Mishra J, Devhare LD and Tiwari An updated review on recent developments and applications of fish collagen. Pharma Times. 2023;55(6):28-36.
  28. Adimulapu AK, Devhare LD, Anasuya Patil A, Chachda NO,Dharmamoorthy. Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases. International Journal of Drug Delivery Technology. 2023;13(3):801-806. DOI: 10.25258/ijddt.13.3.04.
  29. Chawla A, Devhare LD, Dharmamoorthy G, Ritika, TyagiSynthesis and In-vivo Anticancer Evaluation of N-(4- oxo-2- (4 -((5-aryl-1,3,4 thiadiazole-2yl) amino) Phenyl thiazolidine-3-yl) Benzamide derivative. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):470-474. http:// dx.doi.org/10.25258/ijpqa.14.3.02.
  30. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480. DOI: 10.25258/ijpqa.14.3.03.
  31. Sonule M, Devhare LD, Babu MN, Gunjal SD, Varalaxmi S. Microemulgel-based Hydrogel of Diclofenac Sodium using Lipidium sativum as a Gelling Agent. International Journal of Drug Delivery 2023;13(4):1235-1239. DOI: 10.25258/ ijddt.13.4.19.
  32. Shriram BK, Devhare LD, Mehrotra A, Deokar SS, Singh SP. Formulation and Evaluation of Mosquito Repellent International Journal of Drug Delivery Technology. 2023;13(4):1283-1286. DOI: 10.25258/ijddt.13.4.26.
  33. Choudhary RK, Beeraka S, Sarkar BK, Dharmamoorthy G, Devhare L. Optimizing Verapamil Hydrochloride In-situ Delivery: A Strategic Formulation Approach using Box- Behnken Design for Enhanced Performance and Comprehensive Evaluation of Formulation Parameters. International Journal of Drug Delivery Technology. 2024;14(1):61-70. DOI: 10.25258/ 14.1.11.
  34. Kumar KK, Kiran V, Choudhary RK, Devhare LD, Gunjal SD. Design Development and Characterization of Nicardipine SolidLipid Nano-Particulars. International Journal of Drug Delivery Technology. 2024;14(1):71-78. DOI: 10.25258/ijddt.14.1.12.
  35. Priya MGR, Prasanth LML, Devhare LD, Yazdan SK, Gunjal S. Synthesis, DNA Binding, Molecular Docking and Anticancer Studies of Copper (II), Nickel (II), and Zinc (II) Complexes of Primaquine-based Ligand. International Journal of Pharmaceutical Quality Assurance. 2024;15(1):69-75. DOI: 25258/ijpqa.15.1.10.
  36. Uplanchiwar VP, Raut SY, Devhare LD, Tiwari Pharmacological Assessment of Antiulcer Activity of Gloriosa Superba Linn Tubers In Experimentally Induced Gastric Ulcers. Journal of Medical Pharmaceutical and Allied Science. 2021;10(3);2852- 2856. DOI: 10.53555/jptcp.v30i1.2437.
  37. Tiwari G, Gupta M, Devhare LD, Tiwari R. Therapeutic and Phytochemical Properties of Thymoquinone Derived from Nigella Sativa. Current Drug Research Reviews Formerly: Current Drug Abuse 2024;16(2):145-156. Doi:10.2174/ 2589977515666230811092410.